Destiny Pharma plc
DEST.L · LSE
12/31/2023 | 6/30/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.86 | 0.07 | 0.52 | -3.40 |
| FCF Yield | -5.46% | -7.97% | -8.96% | -8.70% |
| EV / EBITDA | -17.28 | -4.08 | -8.38 | -4.96 |
| Quality | ||||
| ROIC | -34.37% | -23.11% | -45.58% | -30.08% |
| Gross Margin | 0.00% | 99.56% | 96.14% | 0.00% |
| Cash Conversion Ratio | 1.21 | 0.69 | 1.06 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 47.72% | 1,038,732.21% | 661,450.53% | 528,234.63% |
| Free Cash Flow Growth | -98.16% | 47.77% | -47.87% | 1.73% |
| Safety | ||||
| Net Debt / EBITDA | 1.83 | 3.04 | 1.20 | 2.19 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -14,083.31 | -27,647.10 | -2,602.46 | -11,592.57 |